NCT00982267View on ClinicalTrials.gov

A Trial Of SU14813 In Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

June 30, 2011

Conditions
NeoplasmsSolid Tumors
Interventions
DRUG

SU014813

Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off

Trial Locations (2)

20246

Pfizer Investigational Site, Hamburg

1081 HV

Pfizer Investigational Site, Amsterdam

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY